XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2025
Revenue Recognition [Abstract]  
Revenue Recognition REVENUE RECOGNITION
Our policies for recognizing sales have not changed from those
described in our Annual Report on Form 10-K for 2024.
We disaggregate our net sales by business and geographic
location for each of our segments as we believe it best depicts
how the nature, amount, timing and certainty of our net sales and
cash flows are affected by economic factors.
In the first quarter 2025 we changed the name of our
Neurovascular business to Vascular due the acquisition of Inari
Medical, Inc. (Inari).
In the fourth quarter 2024 we reorganized our Spine business to
align with certain updates to our internal reporting structure. The
spine enabling technologies portfolio (Enabling Technologies)
was reclassified to Other Orthopaedics and Spine, the
interventional spine (IVS) portfolio was reclassified to Neuro
Cranial and the remaining Spine business was renamed to Spinal
Implants. In addition we changed the name of our "Orthopaedics
and Spine" operating segment to "Orthopaedics."  Neuro Cranial
includes sales related to IVS of $100 and $296 for the three and
nine months 2024. Other Orthopaedics includes sales related to
Enabling Technologies of $32 and $94 for the three and nine
months 2024. We have reflected these changes in all historical
periods presented.
Net Sales by Business
Three Months
Nine Months
2025
2024
2025
2024
MedSurg and Neurotechnology:
Instruments
$760
$679
$2,258
$2,044
Endoscopy
896
837
2,662
2,383
Medical
985
938
2,920
2,710
Vascular
525
329
1,429
966
Neuro Cranial
637
541
1,816
1,533
$3,803
$3,324
$11,085
$9,636
Orthopaedics:
Knees
$628
$570
$1,907
$1,760
Hips
457
420
1,366
1,241
Trauma and Extremities
960
849
2,862
2,511
Spinal Implants
6
172
177
521
Other
203
159
548
490
$2,254
$2,170
$6,860
$6,523
Total
$6,057
$5,494
$17,945
$16,159
Net Sales by Geography
Three Months 2025
Three Months 2024
United
States
International
United
States
International
MedSurg and Neurotechnology:
Instruments
$606
$154
$544
$135
Endoscopy
743
153
689
148
Medical
827
158
783
155
Vascular
283
242
121
208
Neuro Cranial
524
113
448
93
$2,983
$820
$2,585
$739
Orthopaedics:
Knees
$452
$176
$417
$153
Hips
279
178
256
164
Trauma and Extremities
703
257
621
228
Spinal Implants
—
6
119
53
Other
154
49
111
48
$1,588
$666
$1,524
$646
Total
$4,571
$1,486
$4,109
$1,385
Net Sales by Geography
Nine Months 2025
Nine Months 2024
United
States
International
United
States
International
MedSurg and Neurotechnology:
Instruments
$1,814
$444
$1,640
$404
Endoscopy
2,195
467
1,948
435
Medical
2,469
451
2,261
449
Vascular
754
675
369
597
Neuro Cranial
1,496
320
1,255
278
$8,728
$2,357
$7,473
$2,163
Orthopaedics:
Knees
$1,376
$531
$1,279
$481
Hips
831
535
768
473
Trauma and Extremities
2,118
744
1,842
669
Spinal Implants
118
59
361
160
Other
394
154
347
143
$4,837
$2,023
$4,597
$1,926
Total
$13,565
$4,380
$12,070
$4,089
Costs to Obtain or Fulfill a Contract
We typically do not incur costs to fulfill a contract before a
product or service is provided to a customer due to the nature of
our products and services. Our costs to obtain contracts are
typically in the form of sales commissions paid to employees or
third-party agents. Certain sales commissions paid to employees
prior to recognition of sales are recorded as deferred contract
costs. We expense sales commissions associated with obtaining
a contract at the time of the sale or as incurred as the
amortization period is generally less than one year. These costs
have been presented within selling, general and administrative
expenses. On September 30, 2025 and December 31, 2024
deferred contracts costs recorded in our Consolidated Balance
Sheets were not significant.
Contract Assets and Liabilities
Our contract assets primarily relate to conditional rights to
consideration for work completed but not billed at the reporting
date. On September 30, 2025 and December 31, 2024 contract
assets recorded in our Consolidated Balance Sheets were not
significant.
Our contract liabilities arise as a result of consideration received
from customers at inception of contracts for certain businesses or
where the timing of billing for services precedes satisfaction of
our performance obligations. This occurs primarily when payment
is received upfront for certain multi-period extended service
contracts. Our contract liabilities of $939 and $978 on
September 30, 2025 and December 31, 2024 are classified within
accrued expenses and other liabilities and other noncurrent
liabilities in our Consolidated Balance Sheets based on the timing
of when we expect to complete our performance obligations.
Changes in contract liabilities during the nine months 2025 were
as follows:
September 30
2025
Beginning contract liabilities
$978
Revenue recognized from beginning of year contract liabilities
(492)
Net advance consideration received during the period
453
Ending contract liabilities
$939
Transfers and Servicing of Financial Assets
We sell certain customer lease agreements and the related
leased assets to third-party financial institutions to accelerate our
cash collection cycle. The lease receivables are sold without
recourse and are derecognized from our Consolidated Balance
Sheets at the time of sale. Under the terms of our arrangements,
we collect lease payments on behalf of the financial institutions
but maintain no other form of continuing involvement. Sales of
these lease agreements are classified as operating activities in
our Consolidated Statements of Cash Flows. Fees earned for our
servicing activities are immaterial. Revenue related to customer
lease agreements sold under these arrangements represented
less than 4% of our total revenue for the three and nine months
2025 and 2024.